Fennec Pharmaceuticals Inc.

DB:RV41 Stock Report

Market Cap: €193.4m

RV41 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Fennec Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Fennec Pharmaceuticals
Historical stock prices
Current Share PriceUS$6.90
52 Week HighUS$7.25
52 Week LowUS$3.68
Beta0.40
1 Month Change-0.72%
3 Month Change25.45%
1 Year Change24.32%
3 Year Change28.97%
5 Year Change-5.48%
Change since IPO-91.48%

Recent News & Updates

Recent updates

Shareholder Returns

RV41DE BiotechsDE Market
7D4.5%3.1%2.5%
1Y24.3%-12.6%17.1%

Return vs Industry: RV41 exceeded the German Biotechs industry which returned -10.7% over the past year.

Return vs Market: RV41 exceeded the German Market which returned 17.6% over the past year.

Price Volatility

Is RV41's price volatile compared to industry and market?
RV41 volatility
RV41 Average Weekly Movement9.0%
Biotechs Industry Average Movement8.3%
Market Average Movement5.8%
10% most volatile stocks in DE Market12.2%
10% least volatile stocks in DE Market3.1%

Stable Share Price: RV41's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: RV41's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199632Jeff Hackmanfennecpharma.com

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Fennec Pharmaceuticals Inc. Fundamentals Summary

How do Fennec Pharmaceuticals's earnings and revenue compare to its market cap?
RV41 fundamental statistics
Market cap€193.45m
Earnings (TTM)-€12.26m
Revenue (TTM)€26.24m
7.4x
P/S Ratio
-15.9x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RV41 income statement (TTM)
RevenueUS$30.91m
Cost of RevenueUS$3.01m
Gross ProfitUS$27.91m
Other ExpensesUS$42.34m
Earnings-US$14.44m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin90.27%
Net Profit Margin-46.71%
Debt/Equity Ratio-329.1%

How did RV41 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 08:38
End of Day Share Price 2025/06/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fennec Pharmaceuticals Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Naureen QuibriaCapital One Securities, Inc.
Robin Garner KalleyCraig-Hallum Capital Group LLC
Chase KnickerbockerCraig-Hallum Capital Group LLC